Mirus Bio President Russ Smestad plans to leave the company after completion of Roche’s planned acquisition of Mirus (see related story, this issue).
According to Smestad, he will remain with Mirus through the transition period following the acquisition, but will then leave to pursue other opportunities in the biotechnology field.
Isis Pharmaceuticals said last week that it has appointed Martin Bedigian as vice president and chief medical officer.
In this role, Bedigian will be responsible for all medical aspects of Isis' clinical development programs, the company said.
Bedigian previously served as global head of Novartis’ cardiovascular assessment group. He holds an MD from New York Medical College and completed his residency at Emory University.